test

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions

Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Childhood Supratentorial Primitive Neuroectodermal Tumor | Ewing Sarcoma of Bone | Extraosseous Ewing Sarcoma | Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Peripheral Primitive Neuroectodermal Tumor of the Kidney | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

What is the purpose of this trial?

This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma.



Participation Guidelines

Age:
N/A - 50 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Children's Oncology Group
National Cancer Institute (NCI)
Dates:
November 2010
Last Updated:
August 6, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01231906